<生产厂家价格>

替诺昔康

替诺昔康用途

Tenoxicam是抗炎化合物,具有止痛退热活性。

替诺昔康名称

[ CAS 号 ]:
59804-37-4

[ 中文名 ]:
替诺昔康

[ 英文名 ]:
Tenoxicam

[中文别名 ]:

替诺喜康

[英文别名 ]:

Apo-Tenoxicam
Mobiflex
Tenoxicam
Tenoxicamum
Octiveran
Tilcotil
Liman
Novo-Tenoxicam

替诺昔康生物活性

[ 描述 ]:

Tenoxicam是抗炎化合物,具有止痛退热活性。

[ 相关类别 ]:

研究领域 >> 炎症/免疫

[ 靶点 ]

COX-1

COX-2

[参考文献]

[1]. Ozgocmen, S., et al., In vivo effect of celecoxib and tenoxicam on oxidant/ anti-oxidant status of patients with knee osteoarthritis. Ann Clin Lab Sci, 2005. 35(2): p. 137-43.

[2]. Galvao, R.I., et al., Tenoxicam exerts a neuroprotective action after cerebral ischemia in rats. Neurochem Res, 2005. 30(1): p. 39-46.

[相关活性小分子]

替诺昔康物理化学性质

[ 密度 ]:
1.7±0.1 g/cm3

[ 熔点 ]:
209-2130ºC

[ 分子式 ]:
C₁₃H₁₁N₃O₄S₂

[ 分子量 ]:
337.374

[ 精确质量 ]:
337.019104

[ PSA ]:
136.22000

[ LogP ]:
1.52

[ 外观性状 ]:
黄色结晶粉末

[ 折射率 ]:
1.741

[ 储存条件 ]:
-20°C Freezer

[ 水溶解性 ]:
Practically insoluble in water, sparingly soluble in methylene chloride, very slightly soluble in anhydrous ethanol. It dissolves in solutions of acids and alkalis.

替诺昔康MSDS

替诺昔康毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: XJ9095060

CHEMICAL NAME :: 2H-Thieno(2,3-e)-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide

CAS REGISTRY NUMBER :: 59804-37-4

LAST UPDATED :: 199612

DATA ITEMS CITED :: 7

MOLECULAR FORMULA :: C13-H11-N3-O4-S2

MOLECULAR WEIGHT :: 337.39

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 79 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea Nutritional and Gross Metabolic - body temperature decrease

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 12(Suppl 5),759,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 234 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - lacrimation Behavioral - somnolence (general depressed activity) Behavioral - ataxia

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 12(Suppl 5),759,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 186 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - lacrimation Behavioral - somnolence (general depressed activity) Behavioral - ataxia

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 12(Suppl 5),759,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 297 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 12(Suppl 5),759,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 446 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 12(Suppl 5),759,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 449 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 12(Suppl 5),759,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: >128 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 18,1030,1987

替诺昔康安全信息

[ 符号 ]:

GHS06

[ 信号词 ]:
Danger

[ 危害声明 ]:
H301-H311-H331

[ 警示性声明 ]:
P261-P280-P301 + P310-P311

[ 个人防护装备 ]:
Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges

[ 危害码 (欧洲) ]:
T:Toxic

[ 风险声明 (欧洲) ]:
R23/24/25

[ 安全声明 (欧洲) ]:
S36/37/39-S45

[ 危险品运输编码 ]:
UN 2811

[ WGK德国 ]:
2

[ RTECS号 ]:
XJ9095060

[ 海关编码 ]:
2934999090

替诺昔康合成路线

替诺昔康上下游产品

替诺昔康上游产品

替诺昔康下游产品

替诺昔康制备

【方法1】
3-羟基噻吩-2-甲酸甲酯经氯化为3-氯噻吩2-甲酸，用亚硫酸氢钠对氯进行亲核取代后，再甲酯化，生成3-磺基噻吩-2-甲酸甲酯(Ⅱ)，氯化使磺基成为磺酰氯，再对2-甲氨基乙酸乙酯进行酰化，然后在甲醇钠作用下环合，最后和2-氨基吡啶反应生成替诺昔康。

替诺昔康海关

[ 海关编码 ]: 2934999090

[ 中文概述 ]:
2934999090. 其他杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%

[ 申报要素 ]: 品名, 成分含量, 用途

[ Summary ]:
2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

替诺昔康文献

Semi solid matrix formulations of meloxicam and tenoxicam: an in vitro and in vivo evaluation.

Arch. Pharm. Res. 38 , 801-12, (2015)

The objective of this study was to improve the dissolution and subsequently the therapeutic efficacy of poorly water soluble BCS class-II drugs meloxicam and tenoxicam, by lipid semi solid matrix (SSM...

[Turbidimetric determination of tenoxicam using molybdophosphoric acid].

Rev. Med. Chir. Soc. Med. Nat. Iasi. 114(1) , 249-54, (2010)

A turbidimetric method was developed for tenoxicam quantification using the complexing reaction with molybdophosphoric acid in hydrochloric acid medium; the complex has a maximum of absorbance at 369 ...

Effect of age on the pharmacokinetics of tenoxicam in comparison to other non-steroidal anti-inflammatory drugs (NSAIDs).

Scand. J. Rheumatol. Suppl. 80 , 86-9, (1989)

Investigations have shown that elderly patients have an increased sensitivity to the effects of non-steroidal anti-inflammatory drugs (NSAIDs) with a concomitant higher frequency of side-effects. Seve...

更多文献